CN101066255A - Coated ubenimex table - Google Patents
Coated ubenimex table Download PDFInfo
- Publication number
- CN101066255A CN101066255A CNA2007100746426A CN200710074642A CN101066255A CN 101066255 A CN101066255 A CN 101066255A CN A2007100746426 A CNA2007100746426 A CN A2007100746426A CN 200710074642 A CN200710074642 A CN 200710074642A CN 101066255 A CN101066255 A CN 101066255A
- Authority
- CN
- China
- Prior art keywords
- ubenimex
- coated
- table according
- cellulose
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 title claims abstract description 57
- 229950009811 ubenimex Drugs 0.000 title claims abstract description 57
- 239000000463 material Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000000314 lubricant Substances 0.000 claims abstract description 5
- 229920002472 Starch Polymers 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 15
- 239000002775 capsule Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 6
- 238000000576 coating method Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000007919 dispersible tablet Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- -1 polyethylene ketopyrrolidine Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses one kind of coated Ubenimex tablet, which consists of Ubenimex 10-30 weight portions, disintegrant 3-20 weight portions, diluent 50-300 weight portions, lubricant 1-5 weight portions and water soluble coating material 2-20 weight portions. Compared with marketable Ubenimex capsule, the coated Ubenimex tablet has the same dissolution and bioavailability, but simple preparation process and low production cost.
Description
Technical field
The present invention relates to a kind of conventional tablet of ubenimex, specifically, relate to a kind of coated ubenimex table.
Background technology
Ubenimex has obvious curative effects as a kind of immunomodulator to entity tumors such as acute and chronic myelocytic leukemia, lung squamous cancer, nasopharyngeal carcinoma.Ubenimex and conventional chemotherapy or radiotherapy use in conjunction, but the above-mentioned cancer patient's of significant prolongation catabasis and life cycle have obviously improved patient's life quality.
Chinese patent application CN1943562A and CN1706373A disclose a kind of dispersible tablet and the oral cavity disintegration tablet of ubenimex respectively.Ubenimex odorless, bitter in the mouth, in water slightly soluble, belong to insoluble drug.The medicine of mentioning in the dispersible tablet in " Pharmacopoeia of People's Republic of China (version was two ones in 2005) " rules of preparations should be a slightly solubility, thereby ubenimex can be made into dispersible tablet, the another kind of form oral cavity disintegration tablet that also can be made into dispersible tablet improves the disintegrative of ubenimex, and then improve its dissolubility, finally guarantee its dissolution.Therefore, in same alternative adjuvant, dispersible tablet and oral cavity disintegration tablet often need fine disintegrating agent, and consumption is also bigger, to the requirement of other adjuvant also than higher; Simultaneously,, need to adopt advanced production technology and production equipment in order to satisfy the specification requirement of producing these special tablets, thereby its production cost height.At present ubenimex is commercially available only a kind of dosage form of capsule, and patient's selectivity is little.Conventional tablet is applicable to easy dissolving, the material that bioavailability is high, because the ubenimex indissoluble, in order to guarantee its dissolubility and dissolution, research worker is not considered this kind dosage form usually on preparation is selected.
Summary of the invention
Technical problem to be solved by this invention provides a kind of coated ubenimex table.
Coated ubenimex table of the present invention comprises following component and content by weight: 2～20 parts of 10～30 parts of ubenimex, 3～20 parts of disintegrating agents, 50～300 parts of diluent, 1～5 part of lubricant and water-soluble film clothing materials.
Described coated ubenimex table also comprises 1～6 part of binding agent.Described binding agent is selected from least a in water, ethanol, starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethyl cellulose and the syrup, the preferably polyethylene ketopyrrolidine, it mainly acts on is the compressibility that increases label, polyvinylpyrrolidone can increase the wettability of water to tablet, is beneficial to the disintegrate of tablet; In dry granulation, can not select binding agent for use.
Described disintegrating agent is selected from least a in carboxymethyl starch sodium, crospolyvinylpyrrolidone, pregelatinized Starch, cross-linking sodium carboxymethyl cellulose and the low-substituted hydroxypropyl cellulose, preferred carboxymethyl starch sodium, it mainly acts on is to make active constituents of medicine fully release, stripping fast from the tablet skeleton.
Described diluent is selected from least a in lactose, starch, dextrin, microcrystalline Cellulose, Icing Sugar, mannitol and the pregelatinized Starch, preferred lactose, microcrystalline Cellulose and pregelatinized Starch, it mainly acts on is to increase tablet volume, be beneficial to be shaped, increase outward appearance fineness, also can promote the disintegrate of tablet, improve dissolution.
Described lubricant is selected from least a in stearic acid, magnesium stearate, Pulvis Talci, micropowder silica gel and the Polyethylene Glycol, preferred magnesium stearate, and it mainly acts on is to make granule lubricated, increases mobility of particle, improves the compliance of tabletting process.
Film forming polymer in the described water-soluble film clothing material is selected from least a in hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, methylcellulose, sodium carboxymethyl cellulose, Polyethylene Glycol and the polyvinylpyrrolidone.The material commonly used of other interpolations also has plasticizer, antiplastering aid, filler and coloring agent etc.Film forming polymer in the water-soluble film clothing material of commodity Opadry by name is a hydroxypropyl methylcellulose, preferred Opadry II.
In oral solid formulation research to ubenimex, we find unexpectedly, the conventional tablet that ubenimex is made after carrying out film coating, good stability not only, and consistent with the dissolution of commercially available ubenimex capsule (hundred scholars are glad), can satisfy its bioavailability; In addition, because the preparation technology of conventional tablet is simple, adapts to greatly and produce, production cost is lower, has reduced patient's financial burden, and provides alternative peroral dosage form to the patient.
Embodiment below in conjunction with the specific embodiment is described in further detail the present invention.
The specific embodiment
Embodiment 1
Ubenimex 15g
Lactose 68.5g
Pregelatinized Starch 70g
Polyvinylpyrrolidone 3g
Carboxymethyl starch sodium 5g
Magnesium stearate 1.5g
Opadry II 6g
Ubenimex, lactose, microcrystalline Cellulose and carboxymethyl starch sodium are crossed 80～100 mesh sieves, and mix homogeneously adds polyvinylpyrrolidonesolution solution system soft material, with the wet grain of 18～24 mesh sieve systems, cold drying, 18～24 mesh sieve granulate, add carboxymethyl starch sodium and magnesium stearate, mix homogeneously, tabletting.Perhaps, ubenimex, lactose, microcrystalline Cellulose and carboxymethyl starch sodium are crossed 80～100 mesh sieves, mix homogeneously is as bed material, in 25～100 ℃ of fluidized bed granulations, 18～24 mesh sieve granulate add carboxymethyl starch sodium and magnesium stearate with polyvinylpyrrolidonesolution solution, mix homogeneously, tabletting.The label that makes is put in the coating pan, the rolling preheating, in the footpath of coating pan speed is 10～30rpm, the coating pan bed tempertaure is under 30～55 ℃, mode with spraying is sprayed at the sheet wicking surface equably with water solublity coating solution, and dry through the pot bed, the water solublity coating material just forms thin layer at the sheet wicking surface, repeatable operation like this is until forming film-coat.
Embodiment 2
Ubenimex 30g
Lactose 120g
Microcrystalline Cellulose 150g
Cross-linking sodium carboxymethyl cellulose 15g
Stearic acid 5g
Opadry II 20g
With ubenimex, lactose, microcrystalline Cellulose and carboxymethyl starch sodium, cross 80～100 mesh sieves, mix homogeneously with 18～40 mesh sieve dry granulations, adds carboxymethyl starch sodium and magnesium stearate, mix homogeneously, tabletting.The label that makes carries out film coating, and method is with embodiment 1.
In order to investigate the dissolution of coated ubenimex table, measured dissolution by the coated ubenimex table of implementing 1,2 preparations.
With 6 of coated ubenimex tables is solvent with hydrochloric acid solution (dilute hydrochloric acid 24ml adds water to 1000ml) respectively, rotating speed is that per minute 75 changes, sampling in the time of 30 minutes, use high effective liquid chromatography for measuring, the result is as shown in table 1, and its result shows that coated ubenimex table has good dissolution (dissolution of version Chinese Pharmacopoeia regulation ubenimex in 2005 is 80%).
Table 1 coated ubenimex table dissolution
| Embodiment | Dissolution (%) | Meansigma methods | |||||
| 1 | 2 | 3 | 4 | 5 | 6 | ||
| Embodiment 1 | 94.5 | 94.8 | 94.6 | 94.5 | 94.7 | 95.0 | 94.7 |
| Embodiment 2 | 97.7 | 97.8 | 97.6 | 97.2 | 97.6 | 97.6 | 97.6 |
In order to investigate the stripping/release behavior of coated ubenimex table, measured stripping curve by the coated ubenimex table of implementing 1,2 preparations and listing ubenimex capsule (the glad capsule of hundred scholars, specification 30mg).
With 6 of coated ubenimex tables and 6 of listing ubenimex capsules is solvent with hydrochloric acid solution (dilute hydrochloric acid 24ml adds water to 1000ml) respectively, rotating speed is that per minute 75 changes, sampling in the time of 10 minutes, 20 minutes, 30 minutes, 45 minutes respectively, with high effective liquid chromatography for measuring relatively, the result is as shown in table 2.The result shows that coated ubenimex table has and the similar stripping curve of listing ubenimex capsule, shows that coated ubenimex table has and the similar stripping/release behavior of listing ubenimex capsule.
Table 2 stripping curve is measured relatively
| Embodiment | Time (minute) | Dissolution (%) | Average dissolution (%) | |||||
| 1 | 2 | 3 | 4 | 5 | 6 | |||
| Embodiment 1 | 10 | 70.1 | 69.6 | 70.6 | 69.3 | 70.4 | 70.0 | 70.0 |
| 20 | 87.7 | 88.2 | 88.8 | 87.8 | 87.9 | 88.2 | 88.1 | |
| 30 | 95.0 | 95.4 | 95.1 | 95.2 | 95.1 | 95.1 | 95.1 | |
| 45 | 97.5 | 97.5 | 97.7 | 98.0 | 97.6 | 97.6 | 97.7 | |
| Embodiment 2 | 10 | 70.6 | 69.1 | 70.0 | 69.2 | 70.4 | 69.9 | 69.9 |
| 20 | 87.9 | 88.1 | 87.9 | 88.1 | 87.6 | 87.5 | 87.8 | |
| 30 | 95.5 | 94.6 | 95.4 | 95.5 | 95.1 | 94.9 | 95.2 | |
| 45 | 98.0 | 97.7 | 97.5 | 96.6 | 97.8 | 97.5 | 97.5 | |
| Commercially available capsule | 10 | 64.6 | 64.1 | 64.4 | 64.1 | 64.3 | 64.1 | 64.3 |
| 20 | 82.7 | 83.3 | 82.9 | 83.1 | 83.7 | 83.8 | 83.3 | |
| 30 | 93.2 | 94.6 | 94.7 | 94.6 | 94.4 | 94.4 | 94.5 | |
| 45 | 96.6 | 96.6 | 96.5 | 96.9 | 96.8 | 97.1 | 96.7 | |
In order to investigate the stability of coated ubenimex table, the coated ubenimex table of embodiment 1,2 preparations was placed 40 ℃ of accelerated tests 6 months, measure the content of ubenimex, the content and the dissolution of related substance, the result shows that the every index of coated ubenimex table all meets the requirements, stable in properties, quality is good.The results are shown in Table 3.
Table 3 coated ubenimex table accelerated test
| Embodiment | Month | Character | Related substance (%) | Content (%) | Dissolution (%) |
| Embodiment 1 | 0 1 2 3 6 | The coated tablet of the coated tablet white of the coated tablet white of the coated tablet white of the coated tablet white of white | 0.05 0.06 0.07 0.09 0.13 | 100.22 100.14 101.65 101.16 103.54 | 94.16 93.13 93.44 92.19 92.42 |
| Embodiment 2 | 0 1 2 3 6 | The coated tablet of the coated tablet white of the coated tablet white of the coated tablet white of the coated tablet white of white | 0.04 0.07 0.09 0.10 0.12 | 99.98 97.85 98.99 100.90 101.07 | 94.99 94.13 95.55 93.41 95.40 |
Claims (7)
1. a coated ubenimex table is characterized in that, comprises following component and content by weight: 2～20 parts of 10～30 parts of ubenimex, 3～20 parts of disintegrating agents, 50～300 parts of diluent, 1～5 part of lubricant and water-soluble film clothing materials.
2. a kind of coated ubenimex table according to claim 1 is characterized in that, described coated ubenimex table also comprises 1～6 part of binding agent.
3. a kind of coated ubenimex table according to claim 2 is characterized in that, described binding agent is selected from least a in water, ethanol, starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethyl cellulose and the syrup.
4. a kind of coated ubenimex table according to claim 1, it is characterized in that described disintegrating agent is selected from least a in carboxymethyl starch sodium, crospolyvinylpyrrolidone, pregelatinized Starch, cross-linking sodium carboxymethyl cellulose and the low-substituted hydroxypropyl cellulose.
5. a kind of coated ubenimex table according to claim 1 is characterized in that, described diluent is selected from least a in lactose, starch, dextrin, microcrystalline Cellulose, Icing Sugar, mannitol and the pregelatinized Starch.
6. a kind of coated ubenimex table according to claim 1 is characterized in that, described lubricant is selected from least a in stearic acid, magnesium stearate, Pulvis Talci, micropowder silica gel and the Polyethylene Glycol.
7. a kind of coated ubenimex table according to claim 1, it is characterized in that the film forming polymer in the described water-soluble film clothing material is selected from least a in hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, methylcellulose, sodium carboxymethyl cellulose, Polyethylene Glycol and the polyvinylpyrrolidone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100746426A CN100525756C (en) | 2007-05-30 | 2007-05-30 | Coated ubenimex table |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100746426A CN100525756C (en) | 2007-05-30 | 2007-05-30 | Coated ubenimex table |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101066255A true CN101066255A (en) | 2007-11-07 |
| CN100525756C CN100525756C (en) | 2009-08-12 |
Family
ID=38879036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100746426A Active CN100525756C (en) | 2007-05-30 | 2007-05-30 | Coated ubenimex table |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100525756C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342967A (en) * | 2011-09-29 | 2012-02-08 | 青岛国海生物制药有限公司 | Thin film coated tablets containing vitamin, ginseng and zinc sulfate and preparation method thereof |
| CN103142544A (en) * | 2013-02-28 | 2013-06-12 | 成都苑东药业有限公司 | Ubenimex capsule composition and preparation method thereof |
| CN103610663A (en) * | 2013-12-10 | 2014-03-05 | 成都苑东药业有限公司 | Ubenimex capsule medicament composition and preparation method thereof |
| WO2016185232A1 (en) * | 2015-05-18 | 2016-11-24 | Maliaga Tatiana | Food supplement from hazelnut extract and method of producing one such preparation for the therapy of surface and invasive cancer of the bladder |
| CN109464466A (en) * | 2018-11-30 | 2019-03-15 | 无锡福祈制药有限公司 | A kind of spiramvcin Orally administered composition and preparation method thereof |
-
2007
- 2007-05-30 CN CNB2007100746426A patent/CN100525756C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342967A (en) * | 2011-09-29 | 2012-02-08 | 青岛国海生物制药有限公司 | Thin film coated tablets containing vitamin, ginseng and zinc sulfate and preparation method thereof |
| CN103142544A (en) * | 2013-02-28 | 2013-06-12 | 成都苑东药业有限公司 | Ubenimex capsule composition and preparation method thereof |
| CN103142544B (en) * | 2013-02-28 | 2014-01-08 | 成都苑东药业有限公司 | Ubenimex capsule composition and preparation method thereof |
| CN103610663A (en) * | 2013-12-10 | 2014-03-05 | 成都苑东药业有限公司 | Ubenimex capsule medicament composition and preparation method thereof |
| WO2016185232A1 (en) * | 2015-05-18 | 2016-11-24 | Maliaga Tatiana | Food supplement from hazelnut extract and method of producing one such preparation for the therapy of surface and invasive cancer of the bladder |
| CN109464466A (en) * | 2018-11-30 | 2019-03-15 | 无锡福祈制药有限公司 | A kind of spiramvcin Orally administered composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100525756C (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11413295B2 (en) | Oral preparation of obeticholic acid | |
| JP5401327B2 (en) | Tablets with improved dissolution | |
| US20210069207A1 (en) | Pharmaceutical solid preparation comprising benzazepines and production method thereof | |
| JP2009542647A (en) | Memantine pharmaceutical composition | |
| CN103505453B (en) | A kind of orlistat oral solid formulation and preparation method thereof | |
| CN101066255A (en) | Coated ubenimex table | |
| CN106667926B (en) | Favipiravir tablet and preparation method thereof | |
| JP5415561B2 (en) | Pharmaceutical composition comprising a prodrug of an HCV polymerase inhibitor | |
| WO2002087549A1 (en) | Multiple unit type sustained-release tablets | |
| JP2022544167A (en) | Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, method of preparation thereof, and use thereof | |
| CN105030717A (en) | Moxifloxacin hydrochloride film-coated tablet and preparation method thereof | |
| CN111888477B (en) | Bedaquinoline pharmaceutical preparation | |
| CN111228227A (en) | Salbutamol sulfate oral disintegrating tablet and preparation method thereof | |
| CN105147627A (en) | Medicine composition containing pramipexole dihydrochloride and preparation method thereof | |
| CN106983728B (en) | Pramipexole sustained release tablet and preparation method thereof | |
| EP3079672B1 (en) | Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline | |
| KR20060007385A (en) | Solid preparation for oral use | |
| CN112370434B (en) | Entecavir tablet composition and preparation method thereof | |
| WO2022042646A1 (en) | Lurasidone hydrochloride composition and preparation method therefor | |
| HU227070B1 (en) | Immediate release pharmaceutical composition containing ciprofloxacin and process for its production | |
| CN109966256A (en) | A kind of Pramipexole sustained release pharmaceutical composition, preparation method and the usage | |
| CN115463104A (en) | EBTP-containing tablet and preparation method thereof | |
| CN104644601A (en) | Capecitabine tablet | |
| WO2022205576A1 (en) | Preparation method for cefradine capsule | |
| CN117159484A (en) | Acetylcysteine oral preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20071107 Assignee: SINOPHARM CHUAN KANG PHARMACEUTICAL Co.,Ltd. Assignor: SHENZHEN MAIN LUCK PHARMACEUTICALS Inc. Contract record no.: 2013510000056 Denomination of invention: Coated ubenimex table Granted publication date: 20090812 License type: Exclusive License Record date: 20130716 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SINOPHARM CHUAN KANG PHARMACEUTICAL Co.,Ltd. Assignor: SHENZHEN MAIN LUCK PHARMACEUTICALS Inc. Contract record no.: 2013510000056 Date of cancellation: 20231010 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20071107 Assignee: SINOPHARM CHUAN KANG PHARMACEUTICAL Co.,Ltd. Assignor: SHENZHEN MAIN LUCK PHARMACEUTICALS Inc. Contract record no.: X2023510000021 Denomination of invention: Umex film coated tablets Granted publication date: 20090812 License type: Exclusive License Record date: 20231013 |